Abbott to pay $385 million to resolve claims tied to formula factory shutdown
Abbott Laboratories has reached a $385 million settlement related to the 2022 closure of its major U.S. infant formula facility. The shutdown contributed to nationwide shortages of baby formula. The agreement addresses legal claims stemming from the plant's operational halt and its impact on supply.
The settlement resolves legal claims tied to the February 2022 shutdown of Abbott’s Sturgis, Michigan plant, a pivotal event in a months-long national baby formula shortage. Regulators had linked the facility to bacterial contamination concerns, prompting a recall and production halt. The closure strained supply chains already stressed by pandemic-era disruptions, leaving many families scrambling for formula.
Abbott’s $385 million payment addresses allegations that the operational stoppage harmed consumers and retailers. While the company admitted no wrongdoing, the agreement closes a chapter of intense public scrutiny over infant nutrition availability. The funds are expected to compensate affected parties, though specific distribution details remain undisclosed.
This settlement could signal accountability for critical infrastructure failures in essential goods, potentially influencing how manufacturers prioritize safety protocols and supply resilience. Families who endured shortages may see modest financial relief, but broader societal impact lies in rebuilding trust in formula reliability. Regulators and industry may use this case to strengthen oversight, though lasting change depends on proactive measures beyond litigation.